Prof. PeptideProf. Peptide

Curcumin

Recovery & Tissue Repair

Last reviewed: May 26, 2026

Also Known As: Turmeric extract, diferuloylmethane, curcuminoids, BCM-95, Meriva (phytosome), Theracurmin (nanoparticle), Longvida (lipid-coated)

Supplement Class: Polyphenol (turmeric-derived) / NF-κB inhibitor / COX-LOX inhibitor / anti-inflammatory adjunct

Evidence Tier: Strong — Paultre et al. 2021's meta-analysis of 16 RCTs (n=1,810) for knee osteoarthritis with NSAID-comparable effect sizes; Hanai et al. 2006 for ulcerative colitis remission maintenance; Fernández-Lázaro et al. 2020 for exercise recovery; Hewlings & Kalman 2017's review covering the broader evidence landscape. Effect is strongly formulation-dependent (bioavailability gates outcomes).

Buy on Amazon

As an Amazon Associate, Prof. Peptide earns from qualifying purchases.

What is curcumin?

Curcumin is the primary bioactive polyphenol in turmeric (Curcuma longa), the bright yellow spice used for thousands of years in Ayurvedic and traditional Chinese medicine, and now one of the more extensively studied natural compounds in modern supplement research. Its core mechanism is inhibition of NF-κB, the master transcription factor that activates inflammatory gene expression, with secondary inhibition of COX/LOX enzymes (the same pathways NSAIDs target). The reported result is broad anti-inflammatory effects with measurable clinical benefit: NSAID-comparable pain and functional improvement in knee osteoarthritis (Paultre et al. 2021's meta-analysis, n=1,810), maintenance of ulcerative colitis remission (Hanai et al. 2006, roughly 5× lower relapse vs placebo), reduced exercise-induced muscle damage and soreness, modest antidepressant effects, and emerging evidence in cardiovascular and metabolic contexts. The dominant practical challenge for curcumin is bioavailability — standard curcumin powder has near-zero oral absorption, and clinical effect depends on formulation choice. Patented high-bioavailability formulations (Meriva, Theracurmin, BCM-95, Longvida) are reported to produce roughly 7–30× higher plasma curcumin; piperine (BioPerine) co-administration is reported to produce roughly 20× via inhibiting hepatic glucuronidation. Curcumin is discussed alongside healing peptides like BPC-157 and TB-500 since the anti-inflammatory mechanism is complementary to direct tissue-repair signaling.

Reported benefits:

  • Knee osteoarthritis pain reduction and functional improvement (Paultre et al. 2021's meta-analysis, NSAID-comparable)
  • Ulcerative colitis remission maintenance (Hanai et al. 2006, roughly 5× lower relapse vs placebo)
  • Reduced exercise-induced muscle damage and soreness (Fernández-Lázaro et al. 2020)
  • Antidepressant effects comparable to SSRIs in mild-moderate depression (Sanmukhani et al. 2014)
  • Reduced LDL oxidation and improved endothelial function
  • Modest insulin sensitivity improvement
  • Broad NF-κB and COX/LOX inhibition with significantly fewer GI side effects than NSAIDs

Common dose: Formulation-dependent. Meriva 200–500 mg twice daily; Theracurmin 90–180 mg twice daily; BCM-95 500 mg twice daily; standard curcumin plus piperine 1,000–2,000 mg plus 5–20 mg piperine daily. With fat-containing meals. Anti-inflammatory effects are reported to emerge over 4–8 weeks of consistent dosing.

Pre-surgical washout: Stopping curcumin 1–2 weeks before scheduled surgery is standard guidance, given the mild antiplatelet effect. Clinician coordination is standard guidance for users on chronic warfarin, apixaban, rivaroxaban, or clopidogrel.

On this page
  1. 1.How does curcumin work?
  2. 2.What does the evidence say curcumin does?
  3. 3.How is curcumin dosed?
  4. 4.How curcumin is taken
  5. 5.What does curcumin stack with?
  6. 6.Side effects and interactions
  7. 7.What isn't established about curcumin
  8. 8.Product-quality considerations
  9. 9.Curcumin FAQ
  10. 10.References
  11. 11.Published Studies

How does curcumin work?

Curcumin is reported to work primarily through NF-κB inhibition, blocking the master transcription factor that activates inflammatory gene expression. Secondary mechanisms include COX/LOX inhibition (the same pathways NSAIDs target), BDNF upregulation in the brain, and direct free-radical scavenging. The bioavailability problem — standard curcumin is essentially non-absorbed — is the central practical issue gating all of these mechanisms in vivo.

  1. NF-κB inhibition — the primary anti-inflammatory mechanism. Curcumin is reported to directly inhibit IκB kinase, preventing degradation of IκB and blocking NF-κB nuclear translocation, reducing transcription of inflammatory cytokines (TNF-α, IL-1β, IL-6), COX-2, iNOS, and other inflammatory mediators. The breadth of NF-κB's gene targets is discussed as explaining curcumin's wide-spectrum anti-inflammatory effects across joints, gut, vasculature, and neural tissue.
  2. COX/LOX enzyme inhibition. Curcumin is reported to inhibit cyclooxygenase (COX-1 and COX-2) and lipoxygenase enzymes — the same targets as NSAIDs and aspirin — reducing prostaglandin and leukotriene synthesis, discussed as the mechanism underlying curcumin's analgesic and anti-inflammatory effects in joint pain trials.
  3. BDNF upregulation. Curcumin is reported to increase brain-derived neurotrophic factor expression in animal and limited human studies. BDNF supports neuroplasticity and neuronal survival and is reduced in depression and neurodegenerative disease — the mechanistic basis for emerging evidence on curcumin in mood and cognitive applications.
  4. Antioxidant activity. Curcumin is reported to directly scavenge free radicals and upregulate endogenous antioxidant enzymes (superoxide dismutase, catalase, glutathione peroxidase), contributing to cardiovascular and neuroprotective effects documented in preclinical and emerging human evidence.
  5. Bioavailability — the central practical constraint. Standard curcumin is hydrophobic, rapidly conjugated by hepatic glucuronidation/sulfation, and excreted — producing single-digit nanomolar plasma concentrations from gram-doses. High-bioavailability formulations (Meriva phospholipid complex, Theracurmin nanoparticles, BCM-95, Longvida, piperine co-administration) are reported to produce roughly 7–30× higher plasma curcumin, discussed as essential for clinical effect. Standard turmeric powder or generic curcumin at typical supplemental doses is largely inert by oral route.

What does the evidence say curcumin does?

Curcumin has one of the deeper traditional-compound RCT bases in modern dietary supplement research reviewed for this site. The strongest evidence is for osteoarthritis pain (NSAID-comparable in multiple head-to-head trials) and ulcerative colitis maintenance. Exercise recovery, cardiovascular biomarkers, and mood applications are emerging. The clinical evidence is contingent on formulation — standard low-bioavailability curcumin underperforms in most trials reviewed.

  1. Osteoarthritis pain and function (Strong). Paultre et al. 2021's meta-analysis (16 RCTs, n=1,810) reports significant VAS pain reduction and WOMAC functional improvement with curcumin in knee osteoarthritis, comparable to NSAIDs in head-to-head trials with significantly fewer GI adverse events.
  2. Ulcerative colitis remission maintenance (Moderate-Strong). Hanai et al. 2006's RCT (n=89) reports 1 g curcumin twice daily reduced UC relapse rates versus placebo (4.65% vs 20.51%) over 6 months, replicated in subsequent trials.
  3. Exercise-induced muscle damage and soreness (Moderate). Fernández-Lázaro et al. 2020's systematic review reports consistent reductions in CK, inflammatory markers, and muscle soreness with curcumin supplementation around strenuous exercise, with effect sizes described as modest and similar in magnitude to the tart cherry recovery literature.
  4. Depression as adjunct (Moderate). Several RCTs report curcumin produces antidepressant effects comparable to standard SSRIs in mild-to-moderate depression, with a proposed mechanism through BDNF upregulation and anti-inflammatory effects, and effect sizes described as modest.
  5. Cardiovascular biomarkers (Moderate). Curcumin supplementation is reported to modestly reduce LDL oxidation, improve endothelial function, and reduce inflammatory markers (CRP, IL-6) in dyslipidemic populations, with hard cardiovascular outcomes data limited.
  6. Type 2 diabetes prevention (Emerging). A trial in prediabetic adults reports curcumin reduced progression to T2D versus placebo, with mechanisms including improved insulin sensitivity; replication data is thinner.
  7. Cognitive function and Alzheimer's (Emerging). The mechanistic case for BDNF and anti-amyloid effects is discussed as strong; clinical trial results in Alzheimer's and MCI populations have been mixed, partly attributable to bioavailability variation across formulations.
  8. Cancer adjunct (Preclinical/Early). Extensive preclinical evidence exists, with some early human trial data in colorectal and prostate cancer. Whether curcumin meaningfully alters cancer outcomes in humans at supplemental doses remains an open clinical question.

How is curcumin dosed?

Curcumin dosing depends heavily on formulation. A 200 mg dose of Meriva (curcumin-phospholipid complex) is reported to deliver comparable plasma curcumin to 6 g of standard curcumin powder. Selecting a clinically-validated formulation first, then following its trial-validated dose, is the practical approach discussed in the sources reviewed.

Prof. Peptide reports what trials established and what research communities practice, labelled separately. Neither is a recommendation.

  1. Meriva (phytosome complex). 200–500 mg twice daily — the trial-validated range, roughly 29× absorption vs standard curcumin.
  2. Theracurmin (nanoparticle). 90–180 mg twice daily — trial-validated, roughly 27× absorption vs standard.
  3. BCM-95 (curcumin + turmeric oils). 500 mg twice daily — roughly 7× absorption, commonly used in osteoarthritis trials.
  4. Longvida (lipid-coated). 400–800 mg/day — trial-validated, particularly in cognitive applications.
  5. Standard curcumin + piperine. 1,000–2,000 mg curcumin + 5–20 mg piperine (BioPerine) daily — roughly 20× absorption vs curcumin alone, a lower-cost alternative to patented formulations.

Reported timeline: anti-inflammatory and joint-pain effects typically emerge over 4–8 weeks. Exercise-recovery effects are dose-coupled and reported to be operative within 5–10 days of supplementation.

Label math. "Turmeric 1,000 mg with 95% curcuminoids" means 950 mg curcuminoid content, but near-zero plasma absorption without piperine or a bioavailability formulation. Reading "mg of curcumin" without accounting for the absorption profile is misleading; checking for a patented bioavailability formulation name (Meriva, Theracurmin, BCM-95, Longvida) or piperine co-administration is the relevant check.

How curcumin is taken

Curcumin is taken orally as capsules (the dominant form) or occasionally as a powder mixed into golden-milk preparations. Topical use exists for limited cosmetic applications. The practical considerations reported are formulation choice, fat coadministration (curcumin is fat-soluble), and timing relative to other medications.

AspectReported
FrequencyTwice daily is generally preferred, since curcumin's half-life is short (roughly 2 hours) and split dosing maintains steady-state plasma levels. Once daily is used for general purposes.
Best time of dayWith meals, particularly fat-containing meals, for absorption; split AM + PM for steady-state effect. For osteoarthritis pain, timing is discussed as cumulative rather than acute.
FoodWith fat-containing meals is standard guidance, since curcumin is fat-soluble and absorption is meaningfully fat-dependent (less critical, though still helpful, for patented bioavailability formulations).
FormPatented bioavailability formulations (Meriva, Theracurmin, BCM-95, Longvida) for trial-validated absorption; standard curcumin plus piperine (BioPerine) as a lower-cost alternative. Plain turmeric powder or generic curcumin without piperine is discussed as largely inert.
Standardization markerA patented formulation name (Meriva, Theracurmin, BCM-95, Longvida) or "95% curcuminoids + piperine/BioPerine" for the lower-cost option is the clearer standard. "Turmeric extract" with no bioavailability marker does not indicate the absorption needed for the trials reviewed.
CyclingNo cycling is reported as required for general use — chronic daily use is the trial-validated model. For exercise recovery, pulsing around hard training events (5–10 days surrounding) matches the trial protocol.

What does curcumin stack with?

Curcumin is discussed alongside the broader anti-inflammatory and tissue-recovery toolkit. The NF-κB inhibition plus COX/LOX inhibition mechanism is reported as complementary to peptides operating on direct tissue-repair signaling, omega-3 anti-inflammatory effects, and joint-support nutritional adjuncts.

With peptides

Curcumin is discussed alongside the healing peptide cluster. BPC-157 is reported to accelerate tissue repair through angiogenic and growth-factor signaling, particularly relevant for tendon, ligament, and gut injuries. TB-500 (thymosin beta-4 fragment) is reported to support cell migration, wound healing, and tissue regeneration. KPV (an anti-inflammatory tripeptide, the C-terminal of α-MSH) is reported to reduce tissue inflammation via the melanocortin pathway. Curcumin operates at a different layer — NF-κB inhibition and COX/LOX reduction are discussed as blunting the systemic inflammatory background that is often a limiting factor in injury healing. No known negative interaction is documented in the sources reviewed for this page.

With supplements

  1. Omega-3 fish oil — EPA/DHA are reported to modulate different inflammatory pathways (resolvins, protectins) than curcumin, a complementary anti-inflammatory pairing.
  2. Collagen peptides — structural support for joints and connective tissue, complementing curcumin's anti-inflammatory arm for joint health.
  3. Quercetin — an additional anti-inflammatory flavonoid with senolytic effects, a compatible co-occupant in anti-inflammation stacks.
  4. Zinc carnosine — gut-lining support, discussed as pairing with curcumin for IBD or gut-inflammation contexts.
  5. Tart cherry — anthocyanin anti-inflammatory and exercise-recovery effects, compatible with curcumin in training-block recovery protocols.

With lifestyle factors

  1. Fat-containing meals. Curcumin absorption is meaningfully fat-dependent; meal coadministration is reported to improve bioavailability across formulations.
  2. Anti-inflammatory dietary background. A Mediterranean diet, lower omega-6 intake, and reduced ultra-processed food intake are all discussed as reducing baseline inflammation, with curcumin acting on top of dietary factors rather than substituting for them.
  3. Pre-surgical washout. Stopping curcumin 1–2 weeks before scheduled surgery, given the mild antiplatelet effect, is standard guidance.
  4. Hard training blocks. Pulsing 5–10 days surrounding peak training events for exercise-recovery benefits follows the Fernández-Lázaro et al. 2020 protocol.
  5. NSAID rotation. For chronic mild-to-moderate joint pain, alternating periods of curcumin and NSAIDs is discussed as a way to reduce cumulative NSAID GI exposure while maintaining pain control.

Side effects and interactions

Curcumin has a favorable safety profile in the clinical trials reviewed. The main considerations reported are mild GI effects, the antiplatelet interaction with anticoagulants (clinically relevant for surgery and chronic anticoagulation users), and iron-absorption interference.

Common (mostly transient)

  1. Mild GI discomfort — occasional nausea, diarrhea, or stomach upset at higher doses (1 g+), reported to resolve with food coadministration or dose reduction.
  2. Yellow-orange staining of urine or stool — a harmless cosmetic effect from curcumin pigment excretion.
  3. No documented serious adverse events at supplemental doses across the human trial base reviewed.

Less common (watch-list)

  1. Antiplatelet effect (clinically relevant). Mild but documented; relevant for users on anticoagulants and for pre-surgical planning — stopping curcumin 1–2 weeks before scheduled surgery is standard guidance.
  2. Iron absorption interference — curcumin is reported to chelate iron in the gut, potentially reducing absorption; separating iron supplement dosing by 2+ hours is a common mitigation.
  3. Gallbladder issues — curcumin is reported to stimulate gallbladder contraction, which may exacerbate symptoms in users with gallstones or biliary obstruction.

Drug and supplement interactions

  1. Anticoagulants (warfarin, apixaban, rivaroxaban, dabigatran, clopidogrel). An additive antiplatelet/anticoagulant effect is reported; clinician coordination and INR monitoring for warfarin users is standard guidance.
  2. NSAIDs and aspirin. An additive antiplatelet effect with modest additional bleeding risk is reported, generally tolerated but worth flagging for chronic high-dose NSAID users.
  3. Iron supplements — separating dosing by 2+ hours avoids chelation-mediated absorption interference.
  4. Chemotherapy — curcumin has both pro- and anti-cancer effects reported depending on context; some chemotherapy regimens may be affected, so oncologist coordination is standard guidance.
  5. Diabetes medications — curcumin is reported to modestly improve insulin sensitivity, with an additive glucose-lowering effect alongside insulin, sulfonylureas, or GLP peptides; glucose monitoring during titration is standard guidance.
  6. Pregnancy and breastfeeding — high supplemental doses are generally not recommended, though culinary use is considered fine; data for therapeutic dosing safety is insufficient.

What isn't established about curcumin

Curcumin has one of the deeper supplement evidence bases for inflammation and pain reviewed for this site, but several open questions affect how confidently it can be recommended for specific use cases, particularly around formulation-dependent outcome variability, healthy-adult primary-prevention transfer, and the cancer-context dual role.

Formulation-dependent clinical effects. Most negative or null curcumin trials used standard low-bioavailability curcumin where plasma concentrations did not reach effective ranges. Whether higher-bioavailability formulations consistently outperform standard curcumin at equivalent serum levels is mechanistically plausible but not rigorously tested head-to-head at scale in the sources reviewed.

Optimal dose-response curve. Trial doses reviewed range across orders of magnitude (80 mg high-bioavailability formulations to 2,000+ mg standard plus piperine) with comparable outcomes, since actual plasma curcumin matters more than the label mg. The optimal dose-by-formulation curve is not systematically characterized.

Cancer context dual role. Curcumin shows preclinical anti-cancer effects but can interact with chemotherapy in context-specific ways. Clinical implications for users with cancer history or active oncology treatment are not well-defined in the sources reviewed.

Cognitive and Alzheimer's applications. The mechanistic case (BDNF, anti-amyloid) is discussed as strong; clinical trial results in Alzheimer's and MCI populations have been mixed. Whether higher doses, longer duration, or different formulations would produce reliable cognitive benefit is open.

Healthy-adult primary prevention. The strongest evidence reviewed is in symptomatic populations (osteoarthritis pain, ulcerative colitis, post-exercise inflammation). Whether curcumin produces meaningful benefit in asymptomatic healthy adults as a longevity or chronic-disease-prevention intervention is mechanistically reasonable but not directly RCT-supported with hard endpoints.

Multi-year safety at high doses. Trial data reviewed extends to 12 months in many populations. Multi-decade use at supplemental doses is reasonable to infer from the safety profile and culinary history but not directly RCT-characterized.

Product-quality considerations

Curcumin is widely available over-the-counter. Quality variation is unusually large for this supplement, primarily because the bioavailability differences between standard curcumin and patented formulations are roughly 7–30×, making formulation choice the dominant practical quality marker.

Quality markers reported in the category

  • Patented high-bioavailability formulation — Meriva (phytosome), Theracurmin (nanoparticle), BCM-95 (curcumin + turmeric oils), or Longvida (lipid-coated), each with trial-validated absorption behind it.
  • Standard curcumin + piperine (BioPerine) as a lower-cost alternative — 95% curcuminoids plus 5–20 mg piperine, roughly 20× absorption vs curcumin alone.
  • Plain turmeric powder or generic curcumin without piperine/bioavailability formulation is discussed as largely inert at typical supplemental doses.
  • Standardized to 95% curcuminoids — expected on labels for non-patented formulations.
  • Third-party testing — USP, NSF, or ConsumerLab certification, with heavy-metal testing relevant given documented lead-adulteration issues in some turmeric sources.
  • cGMP-certified manufacturing facility.
  • No proprietary blends that obscure the actual curcumin dose alongside fillers.
  • Fresh manufacture date — curcuminoids are reported to degrade with prolonged exposure to heat and light.
Buy on Amazon

As an Amazon Associate, Prof. Peptide earns from qualifying purchases.

Curcumin FAQ

How do standard curcumin, Meriva, BCM-95, and Theracurmin compare?

Bioavailability is the central issue for curcumin — standard curcumin powder has near-zero oral absorption, with single-digit nanomolar plasma levels at standard doses. The high-bioavailability formulations address this in different ways: Meriva (a curcumin-phosphatidylcholine complex) is reported to increase plasma curcumin roughly 29× versus standard; Theracurmin (a nanoparticle dispersion) roughly 27×; BCM-95 (curcumin plus turmeric essential oils) roughly 7×; standard curcumin plus piperine (BioPerine) roughly 20×, via inhibiting hepatic glucuronidation. A common practical approach is selecting one of the patented high-bioavailability forms (Meriva, Theracurmin, Longvida, BCM-95) at trial-validated doses, since standard turmeric powder or generic curcumin extract is largely inert at typical supplemental doses.

How much curcumin is discussed for joint pain?

The relevant dose depends on formulation. With a high-bioavailability formulation: 200–500 mg/day is reported to deliver serum curcumin comparable to gram-doses of standard curcumin. With standard curcumin plus piperine: 1,000–2,000 mg curcumin plus 5–20 mg piperine daily. Paultre et al. 2021's osteoarthritis meta-analysis pooled doses ranging from 80 mg (high-bioavailability formulations) to 2,000 mg (standard plus piperine) and reports consistent pain reduction and functional improvement comparable to NSAIDs — the formulation matters more than the raw mg figure.

Is curcumin reported as comparably effective to ibuprofen for arthritis?

For mild-to-moderate knee osteoarthritis pain, several head-to-head trials report curcumin produces comparable pain reduction and functional improvement to ibuprofen, naproxen, or diclofenac, with significantly fewer GI side effects (ulcer risk, bleeding). Effect sizes for both NSAIDs and curcumin are modest in absolute terms. The practical distinction discussed is safety profile: long-term NSAID use carries cardiovascular and GI risks that long-term curcumin use does not appear to carry. For acute severe pain, NSAIDs are discussed as still faster-acting.

Does curcumin help with exercise recovery and muscle soreness?

Modestly, with reasonable evidence. Multiple trials and a systematic review report curcumin supplementation around hard training events reduces post-exercise muscle damage markers (creatine kinase, lactate dehydrogenase), reduces perceived muscle soreness, and may modestly accelerate strength recovery, with effect sizes smaller than for joint pain. Protocols typically use 150–500 mg of high-bioavailability curcumin daily for roughly a week surrounding a hard training event, a pattern similar to the tart cherry recovery protocol.

Does curcumin stack with BPC-157 or TB-500?

The combination is discussed as mechanistically natural for users targeting tissue recovery and inflammation. BPC-157 is a healing peptide reported to accelerate tissue repair through angiogenic and growth-factor signaling, particularly relevant for tendon, ligament, and gut injuries. TB-500 (thymosin beta-4 fragment) is reported to support cell migration, wound healing, and tissue regeneration. Curcumin operates at a different layer — NF-κB inhibition and COX/LOX reduction are discussed as blunting the systemic inflammatory response that is often a limiting factor in injury healing. KPV (an anti-inflammatory tripeptide) is a third option in this cluster, particularly for users targeting gut inflammation alongside joint or tissue concerns. No known negative interaction is documented in the sources reviewed for this page.

Is curcumin discussed as a concern alongside blood thinners?

Yes — this is the most clinically relevant interaction discussed. Curcumin has documented mild antiplatelet effects, modestly additive with warfarin, aspirin, NSAIDs, clopidogrel, apixaban, and rivaroxaban. For most healthy users, the effect is described as subclinical. For users on chronic anticoagulation or scheduled for surgery, the interaction is more relevant: stopping curcumin 1–2 weeks before scheduled surgery, and clinician coordination for warfarin users (INR monitoring during titration) or other anticoagulants, is standard guidance.

Can culinary turmeric provide the same benefits as supplementation?

Partially, with a substantial gap for systemic effects. Culinary turmeric contains roughly 2–5% curcumin by weight, carrying the same near-zero oral bioavailability problem. Indian-style curries with turmeric typically also include black pepper (piperine) and fat (oil, ghee, coconut milk), which meaningfully improves absorption. Daily turmeric-heavy cooking provides some bioactive curcumin, but the dose is reported to fall far below supplemental ranges — for inflammation-modulating doses (200–500 mg high-bioavailability curcumin daily), supplementation is generally considered necessary.

How long does it take to notice curcumin's effects?

Anti-inflammatory and joint-pain effects are reported to typically emerge over 4–8 weeks of consistent dosing, since the inflammatory pathways curcumin modulates respond on slower timescales than acute analgesics. Some users report modest mood improvements or reduced GI inflammation earlier (2–4 weeks). Evaluation at the 8-week mark, using a high-bioavailability formulation at a trial-validated dose, is standard guidance before concluding curcumin is not producing an effect.

References

  1. Paultre K, Cade W, Hernandez D, Reynolds J, Greif D, Best TM. Therapeutic effects of turmeric or curcumin extract on pain and function for individuals with knee osteoarthritis: a systematic review. BMJ Open Sport Exerc Med. 2021;7(1):e000935. https://pubmed.ncbi.nlm.nih.gov/33500785/
  2. Hewlings SJ, Kalman DS. Curcumin: a review of its effects on human health. Foods. 2017;6(10):92. https://pubmed.ncbi.nlm.nih.gov/29065496/
  3. Fernández-Lázaro D, Mielgo-Ayuso J, Seco Calvo J, Córdova Martínez A, Caballero García A, Fernandez-Lazaro CI. Modulation of exercise-induced muscle damage, inflammation, and oxidative markers by curcumin supplementation in a physically active population: a systematic review. Nutrients. 2020;12(2):501. https://pubmed.ncbi.nlm.nih.gov/32075287/
  4. Hanai H, Iida T, Takeuchi K, et al. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol. 2006;4(12):1502-1506. https://pubmed.ncbi.nlm.nih.gov/17101300/
  5. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm. 2007;4(6):807-818. https://pubmed.ncbi.nlm.nih.gov/17999464/
  6. Sanmukhani J, Satodia V, Trivedi J, et al. Efficacy and safety of curcumin in major depressive disorder: a randomized controlled trial. Phytother Res. 2014;28(4):579-585. Correction: Phytother Res 2024, PMID 38507274. https://pubmed.ncbi.nlm.nih.gov/23832433/

Published Studies

Plain-English summaries of the peer-reviewed studies behind the claims above. Click any title to read the source paper.

BMJ Open Sport & Exercise Medicine · 2021Open Access
Therapeutic Effects of Turmeric or Curcumin Extract on Pain and Function for Individuals with Knee Osteoarthritis: A Systematic Review →

Paultre K, Cade W, Hernandez D, Reynolds J, Greif D, Best TM

A systematic review and meta-analysis of RCTs of turmeric/curcumin extract in knee osteoarthritis. Reports significant pain reduction (VAS score) and functional improvement (WOMAC) versus placebo, with effect sizes comparable to NSAIDs in head-to-head comparisons and significantly lower GI adverse events than NSAID arms.

Foods · 2017Open Access
Curcumin: A Review of Its Effects on Human Health →

Hewlings SJ, Kalman DS

A comprehensive review of curcumin biology, bioavailability solutions, and clinical evidence across inflammatory, metabolic, cardiovascular, neurological, and oncology applications, covering the NF-κB inhibition mechanism and the bioavailability problem that drove development of patented formulations.

Nutrients · 2020Open Access
Modulation of Exercise-Induced Muscle Damage, Inflammation, and Oxidative Markers by Curcumin Supplementation in a Physically Active Population: A Systematic Review →

Fernández-Lázaro D, Mielgo-Ayuso J, Seco Calvo J, Córdova Martínez A, Caballero García A, Fernandez-Lazaro CI

A systematic review of RCTs of curcumin supplementation around strenuous exercise. Reports curcumin significantly reduced post-exercise creatine kinase, inflammatory markers, and muscle soreness versus placebo, with effect sizes described as modest but consistent, mostly using 150–500 mg of high-bioavailability curcumin for 5–10 days surrounding the exercise event.

Clinical Gastroenterology and Hepatology · 2006Paywalled
Curcumin Maintenance Therapy for Ulcerative Colitis: Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial →

Hanai H, Iida T, Takeuchi K, et al.

A randomized double-blind placebo-controlled trial of 1 g curcumin twice daily for 6 months in 89 patients with ulcerative colitis in remission. Reports curcumin significantly reduced relapse rates versus placebo (4.65% vs 20.51%) and improved clinical activity and endoscopic indices — establishing curcumin as an evidence-based maintenance therapy for ulcerative colitis remission.

Molecular Pharmaceutics · 2007Paywalled
Bioavailability of Curcumin: Problems and Promises →

Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB

A foundational review of curcumin bioavailability, documenting that standard curcumin produces single-digit nanomolar plasma levels well below in-vitro effective concentrations, and reviewing the bioavailability-enhancing strategies (piperine co-administration, phospholipid complexes, nanoparticles, liposomal delivery) that subsequent patented formulations were built on.

Anti-InflammatoryNF-κB InhibitorOsteoarthritisBioavailabilityMerivaHealing Cluster

Related Supplements

Fish OilCollagen PeptidesQuercetinZinc CarnosineTart Cherry

Supplement brands

We may earn commissions from peptide vendor affiliate links.

Have a question about Curcumin? Send us an email